Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
TXG 
10X Genomics Inc (TXG)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: TXG (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
16 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $15.08
1 Year Target Price $15.08
| 5 | Strong Buy |
| 2 | Buy |
| 9 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 8.64% | Avg. Invested days 38 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.65B USD | Price to earnings Ratio - | 1Y Target Price 15.08 |
Price to earnings Ratio - | 1Y Target Price 15.08 | ||
Volume (30-day avg) 16 | Beta 2.03 | 52 Weeks Range 6.78 - 24.76 | Updated Date 08/15/2025 |
52 Weeks Range 6.78 - 24.76 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.7 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-08-07 | When - | Estimate -0.37 | Actual 0.28 |
Profitability
Profit Margin -13.13% | Operating Margin (TTM) -2.63% |
Management Effectiveness
Return on Assets (TTM) -9.45% | Return on Equity (TTM) -11.3% |
Valuation
Trailing PE - | Forward PE 196.08 | Enterprise Value 1287735101 | Price to Sales(TTM) 2.56 |
Enterprise Value 1287735101 | Price to Sales(TTM) 2.56 | ||
Enterprise Value to Revenue 2 | Enterprise Value to EBITDA -40.69 | Shares Outstanding 114411000 | Shares Floating 112328879 |
Shares Outstanding 114411000 | Shares Floating 112328879 | ||
Percent Insiders 1.87 | Percent Institutions 110.51 |
Upturn AI SWOT
10X Genomics Inc
Company Overview
History and Background
10X Genomics was founded in 2012. It focuses on developing products that improve genomics analysis. A significant milestone was the launch of the Chromium system. Over time, it has expanded its product portfolio to include single-cell, spatial, and in situ analysis tools.
Core Business Areas
- Single Cell Analysis: Provides tools for high-throughput single-cell gene expression, immune profiling, and multiomics analysis.
- Spatial Biology: Offers solutions for spatially resolved transcriptomics and proteomics, enabling researchers to map gene expression patterns within tissues.
- In Situ Analysis: Developing methods to analyze biological processes directly within cells and tissues, preserving spatial context.
Leadership and Structure
Serge Saxonov serves as CEO. The company has a functional organizational structure, with departments for research, development, sales, and marketing.
Top Products and Market Share
Key Offerings
- Chromium: A microfluidics system enabling single-cell gene expression analysis, immune profiling, and ATAC-seq. Competitors: Illumina (ILMN), Bio-Rad (BIO). While exact market share varies, Chromium is a leading product, capturing a substantial portion of the single-cell analysis market. No revenue data available.
- Visium: Enables spatial gene expression analysis to visualize gene activity in tissue sections. Competitors: Akoya Biosciences (AKYA), NanoString Technologies (NSTG). Market share is growing, but less mature than single-cell, however 10X dominates this category. No revenue data available.
Market Dynamics
Industry Overview
The genomics analysis market is rapidly growing, driven by increasing demand for personalized medicine and drug discovery. Technological advancements are improving analytical capabilities and lowering costs.
Positioning
10X Genomics is a leader in the genomics analysis market, particularly in single-cell and spatial analysis. Its competitive advantages include its innovative technology and comprehensive product portfolio.
Total Addressable Market (TAM)
The genomics analysis TAM is expected to reach over $20 billion by 2027. 10X Genomics is positioned to capture a significant portion of this market due to its innovative technologies and market leadership.
Upturn SWOT Analysis
Strengths
- Innovative technology
- Strong market position in single-cell and spatial analysis
- Comprehensive product portfolio
- Strong brand recognition
Weaknesses
- High product costs may limit adoption in certain markets
- Reliance on single-cell and spatial analysis markets
- Susceptible to IP infringement issues
Opportunities
- Expanding into new markets, such as diagnostics
- Developing new applications for existing technologies
- Acquiring complementary technologies or companies
- Partnerships with research institutions
Threats
- Increasing competition from established and emerging players
- Technological obsolescence
- Economic downturn affecting research funding
- Intellectual property disputes
Competitors and Market Share
Key Competitors
- Illumina (ILMN)
- Bio-Rad (BIO)
- Akoya Biosciences (AKYA)
Competitive Landscape
10X Genomics holds a strong position with innovative technologies. Competitors like Illumina have broader market reach and established customer relationships. Bio-Rad provides different technologies for some overlap. Akoya specializes more specifically in Spatial biology.
Major Acquisitions
ReadCoor
- Year: 2020
- Acquisition Price (USD millions): 350
- Strategic Rationale: Expanded spatial transcriptomics capabilities, bolstering its presence in the spatial biology market.
Growth Trajectory and Initiatives
Historical Growth: 10X Genomics has experienced significant revenue growth in recent years, driven by the adoption of its single-cell and spatial analysis platforms.
Future Projections: Analyst estimates indicate continued revenue growth for 10X Genomics, driven by expansion into new markets and applications.
Recent Initiatives: Recent initiatives include the launch of new products, expansion into new geographic markets, and strategic partnerships.
Summary
10X Genomics is a leader in the genomics analysis market, especially in single-cell and spatial analysis. Its innovative technology and strong market position are working well, however, high costs could limit adoption. 10X Genomics needs to be mindful of increasing competition and technological obsolescence and IP Infringement which is common in this market.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- Analyst reports
- Industry publications
- SEC filings
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market data is subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About 10X Genomics Inc
Exchange NASDAQ | Headquaters Pleasanton, CA, United States | ||
IPO Launch date 2019-09-12 | Co-Founder, CEO & Director Dr. Serge Saxonov Ph.D. | ||
Sector Healthcare | Industry Health Information Services | Full time employees 1306 | Website https://www.10xgenomics.com |
Full time employees 1306 | Website https://www.10xgenomics.com | ||
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the Americas, Europe, the Middle East, Africa, China, and the Asia Pacific. It offers Chromium platform that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; Visium platform includes Spatial Gene Expression, HD Spatial Gene Expression, and Spatial Gene and Protein Expression assays, as well as the Visium CytAssist, an instrument designed to simplify and optimize the Visium solution workflow by facilitating the transfer of transcriptomic analytes from standard glass slides to Visium slides; and Xenium Analyzer instrument enables researchers to detect and preserve the cellular location of hundreds of RNA targets directly in a fresh frozen or FFPE tissue section. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.